Inhibition of apoptosis process and improvement of cell performance
AssigneesThe Johns Hopkins University, Biogen Idec Inc.
InventorsMitchell Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Jr., Marie Hardwick
Life of this patent
Estimating the term…
Abstract
The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.
Claims46
A method for preventing or delaying programmed cell death in an isolated recombinant cell, the method comprising expressing two or more anti-apoptotic polypeptides in the cell such that programmed cell death in the cell is prevented or delayed, wherein the two or more anti-apoptotic polypeptides comprise E1B-19K and Aven, and wherein the cell further comprises heterologous polynucleotides encoding E1B-19K and Aven.
A method of increasing production of a cell-related product by an isolated recombinant cell, the method comprising expressing two or more anti-apoptotic polypeptides in the cell such that production of the cell-related product by the cell is increased, wherein the two or more anti-apoptotic polypeptides comprise E1B-19K and Aven, and wherein the cell further comprises heterologous polynucleotides encoding E1B-19K and Aven.
A method of increasing production of an isolated recombinant cell product, the method comprising expressing two or more anti-apoptotic polypeptides in the cell such that production of the isolated recombinant cell product is increased, wherein the two or more anti-apoptotic polypeptides comprise E1B-19K and Aven, and wherein the cell further comprises heterologous polynucleotides encoding E1B-19K and Aven.
An isolated recombinant cell useful for producing cell-related product expressing two or more anti-apoptotic polypeptides, wherein the two or more anti-apoptotic polypeptides comprise E1B-19K and Aven, and wherein the cell further comprises heterologous polynucleotides encoding E1B-19K and Aven.
A population of isolated recombinant cells useful for producing one or more biological functions of the cells expressing two or more anti-apoptotic polypeptides, wherein the two or more anti-apoptotic polypeptides comprise E1B-19K and Avena and wherein the cell further comprises heterologous polynucleotides encoding E1B-19K and Aven.
Dependencies are inferred from the claim text.